114094Professor and Chairman Emeritus

University of Miami, USA

Memorial Physician Group, Chief, Urologic Oncology, Division of Urology, Florida, USA


Mark Soloway has devoted himself to the subspecialty of urologic oncology for the past 40 years. He has made significant contributions to the understanding and treatment of the three most common GU cancers – prostate, bladder, and kidney.


During his NCI/NIH fellowship he developed an animal model for bladder cancer (BC) which closely resembles its human counterpart and is still being used. Using these primary (carcinogen induced) and transplantable (MBT 2) murine tumors he identified the then experimental drug cisplatin as an active agent for BC. This led to successful clinical trials at MSKCC.


As a young faculty member at The University of Tennessee Dr Soloway was one of the first urologists to prescribe systemic cisplatin chemotherapy to his patients with locally advanced and metastatic BC and seeing the benefits suggested a role for induction or neoadjuvant chemotherapy before cystectomy.

He also demonstrated the synergy between cisplatin and radiation for BC. Once again clinical trials proved the benefit of this approach and it remains a standard for bladder preservation for MIBC.

During his residency at University Hospitals of Cleveland Dr. Soloway’s lab proved that altering the urothelium of the murine bladder allowed tumor cells to implant on the bladder surface and suggested that this is one cause for the high recurrence rate following a TUR BT. He advocated for the use of intravesical chemotherapy following a TUR BT. It is now an accepted standard approach to reduce recurrences.

Dr. Soloway was one of the first to highlight the problem of urothelial carcinoma in the prostate in patients with BC and suggested a staging system which had implications for prognosis and treatment.

Dr. Soloway was one of the first to describe and popularize the periprostatic nerve block before a TRUS guided prostate biopsy procedure now performed over 1 million times annually in the US.


He has co authored numerous articles describing and detailing the implications of a positive margin after RP. He has been a proponent for bladder neck preservation during a RP to minimize the risk of urinary continence and reduce bladder neck strictures.


Working closely with Gaetano Ciancio they have detailed the merits of using liver transplant techniques to reduce the mortality and morbidity of surgery for large renal and adrenal tumors particularly those with an IVC tumor thrombus.

Dr. Soloway received the Gold Cystoscope Award from the AUA in 1984. He was presented with a Presidential Citation from the AUA in 2000 in part for his emphasis on the case presentation method to enhance the interactive aspect of urology meetings.


Dr. Soloway chaired the SIU and ICUD BC recommendations in 2004 and 2011. He has authored over 500 articles in peer reviewed journals.

He  received the Distinguished Career Award from the SIU (2013).

Dr. Soloway delivered the Willet Whitmore Memorial Lecture at the SUO/AUA meeting May 2014. He  received the St Paul medal from BAUS June 2015.